Back to top
more

McKesson (MCK)

(Real Time Quote from BATS)

$586.87 USD

586.87
182,938

+1.13 (0.19%)

Updated Jul 24, 2024 12:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (163 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Should SPDR Russell 1000 Low Volatility Focus ETF (ONEV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for ONEV

McKesson (MCK) Q4 Earnings Beat Estimates, U.S. Sales Strong

by Zacks Equity Research

McKesson's (MCK) fiscal fourth-quarter 2023 results benefit from growth in the United States. Divestment hurt the International segment.

McKesson (MCK) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

The headline numbers for McKesson (MCK) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

McKesson (MCK) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

McKesson (MCK) delivered earnings and revenue surprises of 0.42% and 1.08%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Here's How Inter Parfums (IPAR) is Placed Ahead of Q1 Earnings

by Zacks Equity Research

Inter Parfums' (IPAR) Q1 earnings are expected to reflect gains from robust top-line growth, strength across brands, expansions and product launches.

McKesson (MCK) to Report Q4 Earnings: Is a Beat in Store?

by Zacks Equity Research

McKesson's (MCK) fiscal fourth-quarter results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.

Staar Surgical (STAA) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Staar Surgical (STAA) delivered earnings and revenue surprises of 63.64% and 10.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

McKesson (MCK) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, McKesson (MCK) closed at $361, marking a +1.97% move from the previous day.

SmileDirectClub (SDC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

SmileDirectClub (SDC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AmerisourceBergen (ABC) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

AmerisourceBergen (ABC) delivered earnings and revenue surprises of 6.38% and 4.36%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Is a Beat Likely for Cardinal Health (CAH) in Q3 Earnings?

by Zacks Equity Research

Cardinal Health's (CAH) third-quarter fiscal 2023 results are expected to reflect solid performance in the Pharmaceutical segment. However, inflationary pressure is likely to have continued.

McKesson (MCK) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

What's in Store for DENTSPLY SIRONA (XRAY) in Q1 Earnings?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) first-quarter 2023 results are likely to reflect strong performance in the Technologies & Equipment business.

McKesson (MCK) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, McKesson (MCK) closed at $359.24, marking a -1.11% move from the previous day.

Conmed (CNMD) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Conmed (CNMD) delivered earnings and revenue surprises of 10% and 10.54%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

AmerisourceBergen (ABC) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal 2023 second-quarter results are likely to reflect solid performance in the U.S. Healthcare Solutions segment.

Stryker (SYK) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Stryker's (SYK) first-quarter results are expected to reflect strong segmental performances. However, rising costs are likely to have continued hurting margins.

DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

DexCom's (DXCM) first-quarter results likely to reflect rising volumes across all channels.

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

by Zacks Equity Research

Sector ETF report for PPH

What's in Store for West Pharmaceutical (WST) in Q1 Earnings?

by Zacks Equity Research

West Pharmaceutical's (WST) first-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.

McKesson (MCK) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, McKesson (MCK) closed at $359.27, marking a +1.05% move from the previous day.

Baxter (BAX) to Post Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Baxter's (BAX) first-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.

McKesson (MCK) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

McKesson (MCK) closed the most recent trading day at $362, moving -0.64% from the previous trading session.

Intuitive Surgical (ISRG) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Intuitive Surgical's (ISRG) first-quarter results likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs may have hurt margins.